Clinical trial
An Observational, Multinational, Post-Marketing Registry of Omaveloxolone-Treated Patients With Friedreich's Ataxia
NCT06623890 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational, Multinational, Post-Marketing Registry of Omaveloxolone-Treated Patients With Friedreich's Ataxia
- Lead sponsor
- Biogen
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 12, 2024
- Completion date
- October 1, 2029
- Enrollment
- 300 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.